Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Humoral response to Clostridium difficile in inflammatory bowel disease, including correlation with immunomodulatory treatment.

Henriksson G, Bredberg J, Wullt M, Lyrenäs E, Hindorf U, Ohlsson B, Grip O.

JGH Open. 2018 Dec 28;3(2):154-158. doi: 10.1002/jgh3.12122. eCollection 2019 Apr.

2.

Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients.

Bergenfelz C, Larsson AM, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, Jernström H, Janols H, Wullt M, Bredberg A, Rydén L, Leandersson K.

PLoS One. 2015 May 20;10(5):e0127028. doi: 10.1371/journal.pone.0127028. eCollection 2015.

3.

A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases.

Janols H, Bergenfelz C, Allaoui R, Larsson AM, Rydén L, Björnsson S, Janciauskiene S, Wullt M, Bredberg A, Leandersson K.

J Leukoc Biol. 2014 Nov;96(5):685-93. doi: 10.1189/jlb.5HI0214-074R. Epub 2014 Jun 13.

PMID:
24929004
4.

Heterogeneity among septic shock patients in a set of immunoregulatory markers.

Janols H, Wullt M, Bergenfelz C, Björnsson S, Lickei H, Janciauskiene S, Leandersson K, Bredberg A.

Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):313-24. doi: 10.1007/s10096-013-1957-y. Epub 2013 Aug 29.

5.

Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation.

Bergenfelz C, Janols H, Wullt M, Jirström K, Bredberg A, Leandersson K.

Scand J Immunol. 2013 Aug;78(2):194-204. doi: 10.1111/sji.12075.

6.

Ribotyping of Clostridium difficile strains associated with nosocomial transmission and relapses in a Swedish County.

Magnusson C, Wullt M, Löfgren S, Iveroth P, Akerlund T, Matussek A.

APMIS. 2013 Feb;121(2):153-7. doi: 10.1111/j.1600-0463.2012.02950.x. Epub 2012 Jul 25.

7.

IgG antibody response to toxins A and B in patients with Clostridium difficile infection.

Wullt M, Norén T, Ljungh A, Åkerlund T.

Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.

8.

Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients.

Bergenfelz C, Medrek C, Ekström E, Jirström K, Janols H, Wullt M, Bredberg A, Leandersson K.

J Immunol. 2012 Jun 1;188(11):5448-58. doi: 10.4049/jimmunol.1103378. Epub 2012 Apr 30.

9.

A head-to-head comparison of hydrogen peroxide vapor and aerosol room decontamination systems.

Holmdahl T, Lanbeck P, Wullt M, Walder MH.

Infect Control Hosp Epidemiol. 2011 Sep;32(9):831-6. doi: 10.1086/661104.

PMID:
21828962
10.

[Cleaning and surface disinfection as measure of good hygiene: observations from a hospital bed].

Wullt M.

Lakartidningen. 2011 Mar 9-15;108(10):520-1. Swedish. No abstract available.

PMID:
21744550
11.

Reducing blood culture contamination by a simple informational intervention.

Roth A, Wiklund AE, Pålsson AS, Melander EZ, Wullt M, Cronqvist J, Walder M, Sturegård E.

J Clin Microbiol. 2010 Dec;48(12):4552-8. doi: 10.1128/JCM.00877-10. Epub 2010 Sep 29.

12.

Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders.

Janols H, Bredberg A, Thuvesson I, Janciauskiene S, Grip O, Wullt M.

BMC Infect Dis. 2010 Jul 13;10:205. doi: 10.1186/1471-2334-10-205.

13.

Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics.

Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B.

Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102. doi: 10.1111/j.1399-6576.2008.01748.x.

PMID:
18840110
14.

Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Akerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG.

J Clin Microbiol. 2008 Apr;46(4):1530-3. doi: 10.1128/JCM.01964-07. Epub 2008 Feb 20.

15.

Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.

Odenholt I, Walder M, Wullt M.

Chemotherapy. 2007;53(4):267-74. Epub 2007 Jun 25.

PMID:
17595541
16.

Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea.

Wullt M, Johansson Hagslätt ML, Odenholt I, Berggren A.

Dig Dis Sci. 2007 Sep;52(9):2082-6. Epub 2007 Apr 10.

PMID:
17420953
17.

Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.

Norén T, Akerlund T, Wullt M, Burman LG, Unemo M.

Antimicrob Agents Chemother. 2007 May;51(5):1840-3. Epub 2007 Feb 16.

18.

Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Norén T, Wullt M, Akerlund T, Bäck E, Odenholt I, Burman LG.

Antimicrob Agents Chemother. 2006 Sep;50(9):3028-32.

19.
20.

Activity of three disinfectants and acidified nitrite against Clostridium difficile spores.

Wullt M, Odenholt I, Walder M.

Infect Control Hosp Epidemiol. 2003 Oct;24(10):765-8.

PMID:
14587940
21.

Comparison of AP-PCR typing and PCR-ribotyping for estimation of nosocomial transmission of Clostridium difficile.

Wullt M, Burman LG, Laurell MH, Akerlund T.

J Hosp Infect. 2003 Oct;55(2):124-30.

PMID:
14529637
22.

Supplemental Content

Support Center